A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma

Cetuximab (Cet) and oxaliplatin (OXA) are used as first-line drugs for patients with colorectal carcinoma (CRC). In fact, the heterogeneity of CRC, mainly caused by K-ras mutations and drug resistance, undermines the effectiveness of drugs. Recently, a hydrophobic prodrug, (1E,4E)-6-((S)-1-(isopenty...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta biomaterialia 2024-03, Vol.177, p.456-471
Hauptverfasser:	Song, Huiling, Li, Haosheng, Shen, Xiaonan, Liu, Kuai, Feng, Haoran, Cui, Jiahua, Wei, Wei, Sun, Xiaolu, Fan, Qiong, Bao, Wei, Zhou, Haiyan, Qian, Liheng, Nie, Huizhen, Cheng, Xi, Du, Zixiu
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cell Line, Tumor Cetuximab - pharmacology Cetuximab - therapeutic use Cetuximab-conjugated micelles Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology DMAKO-20 Drug resistance Drug Resistance, Neoplasm EGFR Humans Hydrogen-Ion Concentration K-ras mutations Mutation Nanoparticle Drug Delivery System Oxaliplatin - pharmacology Oxaliplatin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!